Subclinical Atherosclerosis Noted in Diffuse Scleroderma PDF Print E-mail
Saturday, 15 September 2012 14:29
Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis, according to a study published online Aug. 16 in Arthritis Care & Research.

To identify signs of early cardiovascular involvement in SSc, Maurizio Turiel, M.D., of the University of Milan, and colleagues conducted a pilot study involving 20 patients with diffuse SSc but no signs of cardiovascular disease, and 20 age- and gender-matched control patients. The researchers found that arterial wall measurements were significantly different in SSc versus control patients.

Compared with controls, in SSc patients, right and left carotid intima-media thickness, pulse wave velocity, and stiffness index β were also significantly elevated. Coronary flow reserve was significantly lower and plasma levels of asymmetric dimethylarginine levels were significantly higher in those with SSc compared with healthy controls. "In conclusion, patients with diffuse SSc seem to have subclinical cardiovascular involvement, as demonstrated by various methods," the authors write. "Further studies are required to define more precise algorithms for assessing and managing cardiovascular disease in SSc patients."

Source: Healthday (2012), "Subclinical Atherosclerosis Noted in Diffuse Scleroderma"; Original article can be viewed here.

 
More articles :

» Gene Profiling of Scleroderma Skin Reveals Robust Signatures of Disease...

Humphrey Gardner, Jeffrey R. Shearstone, Raj Bandaru, Tom Crowell, Matthew Lynes, Maria Trojanowska, Jaspreet Pannu, Edwin Smith, Stefania Jablonska, Maria Blaszczyk, Filemon K. Tan, and Maureen D. MayesARTHRITIS & RHEUMATISMVol. 54, No. 6, June...

» Apoptosis Modulation as a Promising Target for Treatment of Systemic Sclerosis

St´ephane Chabaud and V´eronique J. MoulinReceived 1 June 2011; Revised 6 July 2011; Accepted 6 July 2011Systemic sclerosis (scleroderma, SSc) is a heterogeneous disease which develops into three forms: limited, intermediate, and diffuse. The...

» Caution Needed When Using ACE Inhibitors in Scleroderma

Exposure to angiotensin-converting enzyme inhibitors prior to the onset of renal crisis in patients with increases the risk of death, according to 1-year findings from the prospective observational International Scleroderma Renal Crisis Survey.The...

» B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence

Dimitrios Daoussis, Stamatis-Nick C. Liossis, Georgios Yiannopoulos, and Andrew P. AndonopoulosDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504 Patras,...

» Lupus and Rheumatoid Arthritis Affect Birth Rates

suggests that more than half of women with the autoimmune diseases (RA) and (SLE, or Lupus) have fewer children than they had desired.According to a study published Thursday in the journal Arthritis Care & Research (a journal of the American...

» Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

Systemic sclerosis is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal...